Trial Profile
Compassionate Use Program For Subcutaneous (SC) Belimumab
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Expanded access; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 28 Feb 2018 Status changed from recruiting to completed.
- 26 Apr 2017 New trial record